Index

Note: Abbreviations used in the index: ADHD = attention-deficit hyperactivity disorder; SUDs = substance use disorders. Page numbers in italic refer to tables.

abuse, childhood 107, 116
acamprosate 210, 215, 223, 225
Adderall XR (MAS XR) 262–4, 269
addiction, definitions 208
see also substance use disorders
adenosine monophosphate (AMP) 281
ADHD 170–1, 251–69
adolescents
ADHD 251, 257–8, 259–60, 261–3, 265–7, 268
antidepressants
Asperger’s spectrum disorders 184, 278
as cause of suicide 33–40, 114
factors in choosing 114
utility of low-dose 184
bipolar disorder 166–7
enrollment in clinical trials 97
impulse control disorders 291, 301–4
Agency for Healthcare Research and Quality (AHRQ) 22
agoraphobia 196, 197–8
akathisia 183, 342–3
alcohol abuse
definitions 208
pharmacotherapies 209, 210, 212, 213–15, 218–19
research issues 222, 223, 224, 225, 226
alprazolam 200
Alzheimer’s disease 281–2, 283, 314, 315, 385
American Academy of Child and Adolescent Psychiatry (AACAP) 82, 83
American College of Medical Genetics (ACMG) 82, 83
American Psychiatric Association (APA) 82, 83
amitriptyline 181–2, 184, 241
AMP A1 52–3
amphetamine, for ADHD 251, 252, 254–5, 262–4, 267, 269
analgesia 181–2
anhedonia 110
animal studies, teratogenicity 94
anorexia nervosa (AN) 234
diagnostic issues 234–5, 236
pharmacotherapy trials 240, 241, 242–3, 244–5, 246–7
anticholinergic effects, antipsychotics 364–6
anticonvulsants
antipsychotic-related seizures 360–1
anticonvulsants (continued)
  anxiety disorders 199, 200, 201
  Asperger’s spectrum disorders 280
  augmentation strategies 113
  bipolar disorder
    acute depression 130
    acute mania 127–9
    combination therapies 137, 153
    cost-effectiveness 138, 139
    crossover study 162, 163–4, 165
    Life Chart rating 156
    maintenance 133–4, 153–5
    prophylactic treatment 135, 136
    protective effect against mortality 139
  defining mood stabilizers 134–5
  eating disorders 241
  impulse control disorders 293, 295, 300, 301–4
  substance use disorders 210, 213, 214, 215, 226
  antidepressants
    acute bipolar depression 130–1
    ADHD 268
    advances in 116–17
    anxiety disorders 197–8, 199, 200, 201
    Asperger’s spectrum disorders 277–9
    as cause of suicide 31–40, 114
    eating disorders 241, 242, 243, 244, 245, 246
    factors in choosing for mood disorders 110–16
    genetics 53–4, 68
    impulse control disorders 292, 293–4, 296–9, 300, 302, 304
    low-dose 179–85
    substance use disorders 210, 217, 218–19, 221, 223, 224
antidiuretic hormone (ADH) 357–9
antsipsychotics
  adverse effects 337–70
    behavioral 183, 281, 318, 324, 339–46
    herbal medicine in schizophrenia 315–19, 324, 357
    low-dose antidepressants for 183
  Asperger’s spectrum disorders 280–1
  bipolar disorder
    acute depression 131
    acute mania 127, 128, 129
    adverse effects 340, 341
    combination therapies 153
    cost-effectiveness 137–9
    Life Chart rating 156
    maintenance 134
    prophylactic treatment 135
    discontinuation symptoms 369–70
    eating disorders 241, 244–5
    generalized anxiety disorder 199
    herbal medicine in schizophrenia 311–27
    herb–antsipsychotic interactions 325–7, 357
    post-traumatic stress disorder 200, 201
    substance use disorders 212, 213, 217
    women in clinical trials 93
  anxiety disorders 191–2
    autism and Asperger’s spectrum disorders 277–9
    comorbidity 111, 150, 151, 152, 192, 199
    generalized anxiety disorder 192, 198–9, 201
    low-dose antidepressants 180, 184, 185
    obsessive compulsive disorder 291, 299, 300, 346
    panic disorder 191–2, 196, 197–8, 201
    post-traumatic stress disorder 200–1
    research issues 192–201
    social anxiety disorder 199–200, 201
  anxious depression 111
  Aricept (donepezil) 282
  aripiprazole
    adverse effects
      behavioral 340, 343, 344, 345
      cardiovascular 352
      metabolic 347, 349
      neuroendocrine 355, 357, 358
      receptor binding affinity 339
      seizures 360
    bipolar disorder 128, 129, 134, 153, 340
  arrhythmias 76, 351–3
  Asperger’s spectrum disorders 273–83
  assessment instruments see rating instruments
  association studies, genes and illness 49, 52–4
atenolol 210
atomoxetine 214, 251, 252, 259–61, 269
attention-deficit hyperactivity disorder (ADHD) 170–1, 251–69
attention deficits
Asperger’s spectrum disorders 281–3
low-dose antidepressants for 183
atypical antipsychotics
adverse effects 337–70
behavioral 183, 281, 339–46
Asperger’s spectrum disorders 280–1
augmentation strategies 113
bipolar disorder
acute depression 131
acute mania 128, 129
combination therapies 153
cost-effectiveness 137–9
Life Chart rating 156
maintenance 134
prophylactic treatment 135
eating disorders 241, 244–5
generalized anxiety disorder 199
post-traumatic stress disorder 200, 201
substance use disorder treatment 212, 213, 217
augmentation strategies, depression 112–13
autism 69, 72, 184, 273–83
autonomy, women 90, 92, 95, 96
B-A-B-A (off-on-off-on) trials 156–9, 160–1
baclofen 210, 281
barbiturates 210
Bayh–Dole Act (1980) 67, 80
behavior therapy
autism 283
trichotillomania 296–9
behavioral effects, antipsychotics 183, 281, 318, 324, 339–46
benzodiazepines
abuse of 211, 216–17
anxiety disorders 197, 198–9
with SSRIs or SNRIs 111
substance use disorder treatment 210, 218
binge eating disorder (BED) 234
diagnostic issues 235, 236
pharmacotherapy trials 240, 241, 243, 244–5, 246
biomarkers 15
bipolar disorder
comorbidity 150, 151, 153, 167–9, 292
genetics 52–3, 113
patent rights 68, 69, 70, 82
management 125–40, 149–71, 279
acute depression 130–2, 150, 151, 152, 154, 166
acute mania 127–9, 150, 151, 152, 154
antipsychotic side effects 340, 341
B-A-B-A trials 156–9, 160–1
childhood-onset 166–7, 170
combination therapies 137, 151–3
comorbidities 150, 151, 153, 167–9
cost-effectiveness 137–9
crossover trials 161–5
factors in treatment choice 109–10, 111, 113, 114
maintenance 132–4, 153–5
N-of-1 trials 156–7, 159–60
prophylactic treatment 135–6, 154–6
protection against mortality 139–40
rating instruments 131–2, 135, 154–6
research methodologies 135–40, 149–71
suggestions for future 170–1
treatment phase definitions 132
treatment resistance 153–4, 155–6
birth control in clinical trials 91–2, 94–5, 96
black box warnings 24, 36, 367
blood pressure, antipsychotics 351, 352
bone mineral density (BMD) 357
brain structure and function see neurobiology
BRCA1 and BRCA2 testing 74–5
breast cancer 182, 355–6
breastfeeding 95–6
brofaromine 200
bulimia nervosa (BN) 234
diagnostic issues 234–5, 236
pharmacotherapy trials 240, 241, 242, 243, 244–5, 246–7
buprenorphine 210, 216, 218, 220, 221
INDEX

bupropion
  acute bipolar depression 130–1
  ADHD 252, 268
  eating disorders 245
  mood disorders 110, 112
  pathological gambling 293
  substance use disorders 213
  utility of low-dose 183, 184
buspirone 113, 278

cannabis abuse 210, 217, 220
carbamazepine
  antipsychotic-related seizures 360–1
  bipolar disorder
    acute depression 130
    acute mania 127, 128, 129
    combination therapies 137, 153
    maintenance 133–4, 154
    prophylactic treatment 135, 136
    protective effect against mortality 139
  choosing for mood disorders 112
  herbal medicine in schizophrenia 326
  substance use disorders 210
cardiovascular problems
  antipsychotic-related 351–4
  patent thickets 76
cataracts 369
catechol-O-methyltransferase (COMT)
  genotype 51, 54, 62–3, 65–6
  Center for Drug Evaluation and Research (CDER) 7, 10, 21
  Centers for Medicare and Medicaid Services (CMS) 15, 22, 24
childhood maltreatment 107, 116
children
  ADHD 170–1, 251–69
  antidepressants
    as cause of suicide 33–40, 114
    factors in choosing 114
  autism and Asperger’s spectrum disorders 273–83
  bipolar disorder 166–7, 170
  FDA reforms 16–17, 19, 33, 35–40
  schizophrenia 274
  see also adolescents
Chinese herbal medicine 311–27
chlorpromazine
  acute mania 127
  adverse effects 338
    behavioral 340, 344
    metabolic 349
    receptor binding affinity 339
    seizures 360
    skin 368
    thromboembolism 367
    herbal medicine compared 316
CIGH syndrome 365
citalopram 183, 184, 295, 304
clinical trials 381–9
  ADHD 251–69
  adverse effects of antipsychotics see antipsychotics, adverse effects
  alternative designs 156–66, 168, 169–70, 386–9
  antidepressants causing suicide 31–40, 114
  anxiety disorders 191–201
  Asperger’s spectrum disorders 273–83
  eating disorders 233–47
  FDA reform 3–27
  herbal medicine for schizophrenia 311–27
  history 381–3
  impulse control disorders 289–304
  meta-analyses 387–8
  methodological assumptions 383–5
  mood disorders 105–17
  see also bipolar disorder
  psychiatric genetics 43–56, 61–83
  substance use disorders 207–27
  women’s issues 87–98
clomipramine
  acute bipolar depression 131
  adverse effects 346
  trichotillomania 296–9
  utility of low-dose 180, 183, 184–5
clonazepam 303, 304
clonidine 210, 216, 278
clozapine
  acute bipolar mania 127
  adverse effects 338
    anticholinergic 364–5, 366
    behavioral 340, 341, 342, 344, 345, 346
    cardiovascular 351, 352, 353–4
    CIGH syndrome 365
    discontinuation symptoms 369–70
hematological 363, 364
immunological 368
metabolic 347, 348, 349, 350
mortality 368
neuroendocrine 355, 358
pancreatitis 369
receptor binding affinity 338, 339
seizures 360
thromboembolism 367
Asperger’s spectrum disorders 281
herbal medicine and 316, 317, 325–6
cocaine abuse 210, 212, 221, 224
Cognex 281–2, 385
cognition
Asperger’s spectrum disorders 281–3
low-dose antidepressants 183
schizophrenia
antipsychotic side effects 366
heritage 51–2, 54, 62–3
herbal medicine 313–14, 316
Cognitive behavioral therapy (CBT)
eating disorders 246
generalized anxiety disorder 199
mood disorders 116
post-traumatic stress disorder 201
social anxiety disorder 200
substance use disorders 218–19, 223
comorbidity
anxiety disorders 111, 150, 151, 152, 192, 199
Asperger’s spectrum disorders 278, 279–81
bipolar disorder 150, 151, 153, 167–9, 292
eating disorders 235, 242
impulse control disorders 292, 299
substance use disorders 150, 151, 152, 220–1
comparative effectiveness research 21–3
see also efficacy–effectiveness gap
compliance
eating disorder trials 243
substance use disorder trials 223
COMT (catechol-O-methyltransferase)
genotype 51, 54, 62–3, 65–6
Concerta (OROS MPH) 264–6, 269
consent forms, women 97
constipation 364–5
contraception in clinical trials 91–2, 94–5, 96
contracted clinical trials 245
cost-effectiveness, bipolar disorder drugs 137–9
Critical Path Initiative 3, 14–17, 19, 21, 26
crossover trials
bipolar disorder 161–5
herbal medicine in schizophrenia 322–3
post-traumatic stress disorder 201
crying, pathological 184
cutaneous effects, antipsychotics 368
cyclic adenosine monophosphate (cAMP) 281
cyproheptadine 183
cytochrome p450 genes 54, 63
Daytrana (MTS) 252, 255–6
deep brain stimulation 113, 342
defibril, clozapine-induced 366
dementia 281–2, 283, 314, 315, 385
deoxribonucleic acid methyltransferase (DNMT) 51, 55
depression
Asperger’s spectrum disorders 277, 278, 279
in bipolar disorder see bipolar disorder
epidemiological data 106
heritage 53–4, 68, 69, 107, 113
low-dose antidepressants 180
treatment
advances in 116–17
antidepressants causing suicide 31–40, 114
factors in choosing 109–16
issues in 108–9
desipramine 110, 130, 200
detoxification, substance dependence 218
diabetes 348–9, 350
diagnostics, psychiatric genetics 61, 64, 65–83
diazepam 210, 214
dilated cardiomyopathy (DCM) 353–4
discontinuation, antipsychotics 369–70
disulfiram 210, 212
DNA 46, 48–9, 50, 51, 55

donepezil (Aricept) 282

double-blind procedures 221–2, 384–5
doxepin, for insomnia 180
drug abuse see substance use disorders
drug development 44–5
drug efficacy–effectiveness gap 151, 153
drug lag 8–9
drug pipeline problem 3, 12–17
drug safety
  antidepressants causing suicide 31–40, 114
  FDA reforms 3, 4–5, 6, 9–12, 18–21, 23, 24
  herbal agents 323–4, 325
  SUD treatment trials 224, 227
  women’s issues in clinical trials 87–98
see also antipsychotics, adverse effects
drug screening, patents 68–9
dystonia 342, 343
eating disorders 233–47
  diagnostic issues 234–7
  methodological/statistical issues 237–40
  pharmacotherapy trials 240–6
  psychotherapy trials 246
efficacy–effectiveness gap 135–6, 151, 153
elderly people
  antipsychotic side effects 341, 366, 367
  anxiety disorders 193
  depression 114
  insomnia 180
  electroconvulsive therapy 112, 113
  emotion regulation 184–5
  endophenotypes 62
  epigenetics 62
escitalopram
  impulse control disorders 294, 300, 301–4
  social anxiety disorder 200, 201
estrogen skin patches 95
estrogen therapy 113, 115
ethanol, substance use disorders 214
ethics
  eating disorder trials 243–4
substance use disorders 211, 220
  women in clinical trials 90, 95, 96
ethnic minorities 90–1, 93, 97–8
see also ethnicity
ethniciy 115–16, 193
European Society of Human Genetics (ESHG) 79
experimental drugs, access to 5–6, 24–5
extrapyramidal symptoms 339–43
family history, mood disorders 113
FDA see Food and Drug Administration
FDAAA 18–20
fetal protection, clinical trials 87–98
flumazenil 210, 211
fluoxetine
  acute bipolar depression 131
  eating disorders 241, 242, 243, 245
  impulse control disorders 296–9, 300, 301–4
  mood disorders 115–16, 131
  substance use disorders 223, 224
  utility of low-dose 182, 184
fluvoxamine
  pathological gambling 293, 294
  social anxiety disorder 200
  Focalin (d-MPH) 252, 256–7
  Focalin XR (d-MPH-ER) 252, 257–9, 269
folate 210
Food and Drug Administration Act
  Amendments 2007 (FDAAA) 18–20
Food and Drug Administration (FDA) 3–27
ADHD 251–2, 253–66, 269
antipsychotic-related mortality 367
Asperger’s spectrum disorders 280–1
bipolar disorder
  acute depression 131
  acute mania 127
  efficacy–effectiveness gap 151, 153
  maintenance 132, 134
  mood stabilizers 134
  RCT alternatives 157–9
eating disorders 245
  pediatric studies 16–17, 19, 33, 35–40
  suicide in adolescents 33, 35–40
thalidomide 88–9
  women in clinical trials 88–90, 91, 97
Free and Easy Wanderer Plus (FEWP) 323, 324, 326
funding
  bipolar disorder trials 170–1
  comparative effectiveness research 23
eating disorder trials 241, 245–6
Food and Drug Administration 21
history of clinical trials 381–2


gabapentin
  bipolar disorder
    acute mania 128–9
    combination therapies 153
crossover study 162, 163–4, 165
protection effect against mortality 139
extrapyramidal symptoms 341–2
substance use disorders 215
gambling, pathological 289–90, 291–2, 293–5
gastrointestinal problems 181, 364–5
gender variables see sex-related response differences
gene therapy 55
generalized anxiety disorder (GAD) 192, 198–9, 201
genomics and genetics 43–56, 61–3
  Asperger’s spectrum disorders 275–6
  mood disorders 52–4
    factors in choosing treatment 113
    gene-based patent rights 68, 69, 70, 82
    patents and licensing 61, 63–83
gepirone 37–8
ginkgo biloba 315, 316, 317
global environment, drug regulation 4, 27
glutocorticoid receptors 53–4
  bipolar disorder 52–3
  major depressive disorder 53
  guanfacine 251, 266–7, 269, 278

habit-reversal therapy (HRT) 296–9
hair pulling (trichotillomania) 289–90, 292, 296–9
haloperidol
  adverse effects 338
    behavioral 340, 343, 344, 345
    metabolic 347–8, 349
  neuroendocrine 355, 356, 357
  pancreatitis 369
  receptor binding affinity 338, 339
  thromboembolism 367
  bipolar disorder 127, 129, 138
  herbal medicine in schizophrenia 317, 325–6
  Hamilton Rating Scale for Depression (HAM-D) 132, 154, 156
  haplotypes 48–9
  health insurance 36, 37
  hematological effects, antipsychotics 363–4
  hepatic effects, antipsychotics 363
  herbal medicine
    hyperprolactinemia 318–19, 357
    schizophrenia 311–27
  heroin abuse 211, 216, 221, 223
  hormonal contraceptives 95
  hormone-related issues
    antipsychotics 318–19, 345, 354–9
    low-dose antidepressants for 182
  hormone therapy 113, 115
  hot flashes 182
  huperzine A (HupA) 313–14
  hypericum perforatum 323
  hyperlipidemia 349, 350
  hyperprolactinemia 318–19, 345, 354–7
  hypersonmnia 111
  hypertension 352
  hyponatremia 358
  hypotension 351
  imipramine
    bipolar disorder 130, 132
    generalized anxiety disorder 199, 201
  immunological effects, antipsychotics 368
  impulse control disorders (ICDs) 289–304
  individualized treatment strategies 321–3
  insomnia 180
  intellectual property 61, 63–83
  intent-to-treat (ITT) analyses 222
  intermittent explosive disorder (IED) 289–90, 304
  investigator initiated trials (IITs) 245–6
  irritable bowel syndrome 181
kainate-type glutamate receptor gene (GRIK4) 54

kleptomania 289–90, 299–301

lactating women 95–6

lamotrigine

bipolar disorder

acute depression 130
combination therapies 153
crossover study 162, 163–4, 165
maintenance 134, 154, 155
prophylactic treatment 135
post-traumatic stress disorder 200

last observation carried forward (LOCF) 222, 239, 386

laughing, pathological 184

levetiracetam 213

liability litigation 24

see also malpractice risk

licensing, diagnostic patents 61, 64, 66–7, 74–6, 77–80, 83

Life Chart Method (LCM) 135, 154–5, 156

linkage analyses 49

Lisdexamfetamine dimesylate (LDX; Vyvanse) 252, 253–5, 269

lithium 125–6

Asperger’s spectrum disorders 280

bipolar disorder

acute depression 130
acute mania 127
combination therapies 137, 153
cost-effectiveness 137, 138–9
maintenance 132–4, 153–4
prophylactic treatment 135–7
protection against mortality 139–40
factors in choosing 112, 113–14, 116
impulse control disorders

kleptomania 300
pathological gambling 294, 295
pyromania 301–4

neuroprotective effects 52

lofexidine 210

Long QT Syndrome (LQTS) 76

loxapine 338, 339

neuroprotective effects 52

lofexidine 210

Long QT Syndrome (LQTS) 76

loxapine 338, 339

magnetic seizure therapy 113

major depressive disorder (MDD) 53–4, 68

malpractice risk, antidepressants 37

see also liability litigation

mania

antipsychotic-related 345–6
in bipolar disorder see bipolar disorder

march-in rights 80

mediator variables 167–9

medical product agencies 25–6

Medicare 15, 22, 24

Medicare Prescription Drug, Improvement and Modernization Act (2003) 22

melancholic patients 112

melatonin 216

memantine 283

memory deficits

antipsychotic side effects 366

Asperger’s spectrum disorders 281–3

herbal medicine in schizophrenia 314

low-dose antidepressants for 183

men

fetal risk in clinical trials 91–2, 94–5, 96

low-dose antidepressants 182, 183

mood disorder treatments 115

menopause 115, 182

met/met genotype 51, 54

meta-analyses 387–8

metabolic effects, antipsychotics 346–50

Medication CD (MPH MR) 252, 261

methadone 210, 215, 218, 219, 221, 224

methamphetamine 212–13

methylphenidate 251–2, 255–9, 261, 264–6, 269

mianserin 180, 183

minorities see ethnic minorities; ethnicity

mirtazapine 180, 181, 182, 183, 184

missing data 222, 239, 386

modafinil 113, 210, 252, 267–8

moderator variables 167–9

monamine-oxidase inhibitors 110, 115

Montgomery–Asberg Depression Rating Scale (MADRS) 131–2, 154, 156

mood disorders 105–17

advances in treatment 116–17

antidepressants causing suicide 31–40, 114

Asperger’s spectrum disorders 279–81

bipolar disorder see bipolar disorder

epidemiological data 106
factors in choosing drug treatment 109–16

genetics 52–4, 68, 69, 70, 82, 113

issues in treatment 108–9

low-dose antidepressants 179–85


mood stabilizers

antidepressants causing suicide 38, 39

Asperger’s spectrum disorders 280, 283

bipolar disorder

acute depression 130

acute mania 127–9

combination therapies 137, 153

crossover study 162, 163–4, 165

Life Chart rating 156

maintenance 132–4, 153–5

prophylactic treatment 135–6

protection against mortality 139–40

definitions 134–5

factors in choosing 110, 111, 113

impulse control disorders 292, 294, 295, 300, 301–4

mortality

antipsychotics 367–8

bipolar disorder 139–40

movement disorders 183, 281, 318, 324, 339–43

myocarditis 353–4

Myriad Genetics, Inc. 68–9, 74–5

N-of-1 trials 156–7, 159–60, 322

nalmefene 211, 214, 294

naloxone 210, 211, 216

naltrexone

impulse control disorders 293, 294, 301, 302

substance use disorders 210, 212, 213, 214–15

research issues 220, 222, 223, 225, 226

National Institute of Mental Health (NIMH) 135, 154–5, 156, 167, 168

National Institutes of Health (NIH)

FDA reforms 12–13, 26

genetic diagnostics 80

history of clinical trials 381–2

women in clinical trials 90–1, 92, 93

naturalistic studies, bipolar disorder 135–6, 139, 152–3

nausea 181

nefazodone 111, 116, 295

neurobiology

adverse effects of antipsychotics 338–9

Asperger’s spectrum disorders 277, 281–3

bipolar disorder 52–3

major depressive disorder 53–4

mRNA studies 49–50

schizophrenia 50–2, 54, 62–3

herbal medicine in schizophrenia 313, 314, 319, 320

impulse control disorders 290–1, 300, 304

low-dose antidepressants 184–5

mood disorders 106–7, 108

genetics 52–4, 107

treatment advances 116–17

treatment choices 110, 115

research technology 44, 45–6

substance use disorders 208, 209

neuroendocrine effects, antipsychotics 318–19, 345, 354–9

neuroleptic malignant syndrome (NMS) 361–3

neuroleptics see antipsychotics

nicotine replacement, transdermal 214

α-7 nicotinic receptor 51–2

non-inferiority trials, FDA reforms 23

observational studies, bipolar disorder 135–6, 139, 152–3

obsessive compulsive disorder (OCD) 291, 299, 300, 346

obsessive compulsive symptoms (OCSs) 346

off-on-off-on (B-A-B-A) trials 156–9, 160–1

olanzapine

adverse effects 338

anticholinergic 365, 366

behavioral 340, 341, 344, 346

cardiovascular 351, 353

cataracts 369

metabolic 347–9
olanzapine (continued)

  neuroendocrine 355, 356, 358
  pancreatitis 369
  receptor binding affinity 339
  seizures 360
  Asperger’s spectrum disorders 281
  bipolar disorder 128, 129, 131, 134, 135, 138–9
  generalized anxiety disorder 199
  herbal medicine in schizophrenia 316, 325–6
  post-traumatic stress disorder 200
  pyromania 301–4
  substance use disorders 217

ondansetron

  eating disorders 241
  substance use disorders 212
  opiate abuse 210, 211, 215–16, 218
  research issues 219, 220, 221, 223, 224
  opiates, for psychache 110
  opioid antagonists
    impulse control disorders 292, 293, 294, 300–1, 302
    substance use disorders 210, 211, 212–16
    research issues 220, 222, 223, 225, 226

see also buprenorphine

OROS methylphenidate (OROS MPH; Concerta) 264–6, 269
orthostatic hypotension 351
outcome measures, SUD treatment trials 225–6
overdoses, reversal 210, 211
own control study designs 386–7
oxcarbazepine
  bipolar disorder 134
  substance use disorders 214, 215

pain

  chronic 181–2
  psychological (psychache) 110
  pancreatitis 369
  panic disorder 191–2, 197–8, 201
  low-dose antidepressants 180, 184
  symptom assessment 196
  parkinsonism 339–40, 343
  paroxetine
    acute bipolar depression 130

factors in choosing 116
  generalized anxiety disorder 199, 201
  pathological gambling 293, 294
  post-traumatic stress disorder 200, 201
  social anxiety disorder 200, 201
  substance use disorders 217
  utility of low-dose 182, 184

patent fragmentation 61
patent pools 80–3
patent thickets 75–6, 78–9, 81, 83
patents, psychiatric genetics 61, 63–83
pathological gambling (PG) 289–90, 291–2, 293–5

PDUFA 3, 7–11, 18–19, 21
pediatric studies see children
perphenazine 338, 339, 340, 343
pharmacogenetics 54–5, 63
  patents 68, 73–4
phenomena of nature limitation 65–6
phobic disorders 192, 196, 197–8
phosphodiesterases (PDE) 53
pindolol 113, 198, 200
placebos 324–5, 385
politics, antidepressants 35–40
polydipsia (potomania) 358, 359
post-traumatic stress disorder (PTSD) 200–1
prazosin 201
pregabalin 199, 201
pregnancy 87–98
premature ejaculation 183
premenstrual symptoms 182
Prescription Drug User Fee Act 1992
(PDUFA) 3, 7–11, 18–19, 21
prolactin 318–19, 345, 354–7
proof of principle trials 156–9
prostate cancer 182
protein kinase C (PKC) 52
proteomics 48
psychache (psychological pain) 110
psychometric instruments see rating instruments
psychosocial functioning 138–9, 154
psychotherapy
  anxiety disorders 197–8, 199, 200, 201, 201
  autism 283
  choosing for mood disorders 111–12, 113, 114, 116
eating disorders 246
substance use disorders 218–19, 222–4
public health, gene-based patents 79–80
public policy, antidepressants 35–40
pulmonary embolism 367
pyromania 289–90, 301–4
QT interval 76, 352–3
quality controls, herbal medicine 323–4
quality-of-life assessments 138–9
quetiapine
adverse effects
anticholinergic 364, 365
behavioral 340, 341, 344, 345
cardiovascular 351
cataracts 369
discontinuation symptoms 370
metabolic 349
neuroendocrine 355, 358
receptor binding affinity 339
seizures 360
Asperger’s spectrum disorders 281
bipolar disorder
acute mania 128
adverse effects 340
cost-effectiveness 138
Life Chart rating 156
maintenance 134
herbal medicine in schizophrenia 325–6
substance use disorders 213
randomized controlled trials (RCTs)
anxiety disorders 191, 192, 194–6, 198–200, 201
bipolar disorder 126, 127, 149, 150
acute depression 130, 131, 150
acute mania 127–8, 150
combination therapies 153
maintenance 132, 133–4
mediator/moderator variables 167–8
non-traditional designs 156–66, 168, 169–70
eating disorders 237–42, 243–4
herbal medicine 321–2
non-traditional designs 156–66, 168, 169–70, 322–3
substance use disorders 221
rating instruments
ADHD 252
anxiety disorders 194–6
bipolar disorder 131–2, 135, 154–6
eating disorders 236–7, 244
reboxetine 110, 112, 221, 224
recruitment
SUD treatment trials 219–20
women in clinical trials 93, 97–8
reelin 50–1
reminyl 283
reproductive-age women
clinical trials 87–98
low-dose antidepressants 182
restless legs syndrome 183
retention
eating disorder trials 243
SUD treatment trials 222–3
of women in clinical trials 97–8
retinopathies 369
rimonabant 213, 217
Risk Evaluation and Mitigation Strategies (REMS) 8, 19–20
risperidone
adverse effects 338
anticholinergic 365
behavioral 340, 341, 344, 345
cardiovascular 351, 353
metabolic 347–8, 349
neuroendocrine 355, 356, 357, 358
pancreatitis 369
receptor binding affinity 339
seizures 360
Asperger’s spectrum disorders 280–1
bipolar disorder 128, 129, 138, 340
generalized anxiety disorder 199
herbal medicine in schizophrenia 317, 319, 325–6
post-traumatic stress disorder 201
substance use disorders 212, 217
Ritalin LA 252, 261
ritanserin 183
rivastigmine 212, 283
RNA
gene therapy 55
messenger (mRNA) 47
brain abnormality studies 49–50, 53–4
RNA (continued)
  major depressive disorder  53–4
  transfer RNA (tRNA)  47

safety
  antidepressants  31–40, 114
  FDA reforms  3, 4–5, 6, 9–12, 18–21, 23, 24
  herbal agents  323–4, 325
  SUD treatment trials  224, 227
  women in clinical trials  87–98
  see also antipsychotics, adverse effects
saliva, sialorrhea  368–9
schizophrenia
  childhood  274
  genetics  49, 50–2, 54, 62–3
  patents  65–6, 67, 68, 69, 71, 76
  herbal medicine  311–27
  women in clinical trials  93
  see also antipsychotics, adverse effects
second-generation antipsychotics (SGAs)
  see atypical antipsychotics
sedative effect, antipsychotics  343–4
sedative-hypnotics abuse  210
seizures, antipsychotics  360–1
selective serotonin reuptake inhibitors (SSRIs)
  acute bipolar depression  130, 131
  anxiety disorders  197, 199, 200, 201
  Asperger’s spectrum disorders  277–9
  choosing for mood disorders  111, 112, 114, 115–16
  eating disorders  241, 242, 243, 245
  impulse control disorders
    intermittent explosive disorder  304
    kleptomania  300
    pathological gambling  292, 293, 294, 295
    pyromania  301–4
    trichotillomania  296–9
    substance use disorders  210, 217, 218–19, 223, 224
  utility of low-dose  182, 183, 184
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)  54
  anxiety  111
  bipolar disorder  152
  practical approaches  161
  serotonin 2A receptor gene (5HTR2A)  54
  serotonin-norepinephrine reuptake inhibitors (SNRIs)  111, 182
  serotonin-specific reuptake inhibitors see selective serotonin reuptake inhibitors (SSRIs)
sertraline
  impulse control disorders  295, 296–9, 301–4
  post-traumatic stress disorder  200, 201
  social anxiety disorder  200, 201
  substance use disorders  218–19
  utility of low-dose  182, 184
settings
  eating disorder trials  243
  substance use disorder trials  227
sex-related response differences
  anxiety disorder treatment  193
  mood disorder treatment  115
  women in clinical trials  90–1, 92–3
sexual dysfunction  183, 344–5
SGAs see atypical antipsychotics
SIADH  357–9
sialorrhea  368–9
signal transduction cascades  47, 52, 53
single case randomized controlled trials (SCRCTs; N-of-1 trials)  156–7, 159–60, 322
single nucleotide polymorphisms (SNPs)  48–9, 51, 62–3, 65–6
sinus arrhythmias  351–2
skin rashes  368
sleep disturbances
  antipsychotic-related  343–4
  low-dose antidepressants for  180
  treatment for mood disorders  111
social anxiety disorder  199–200, 201
social isolation  277–9
social phobia  192
SPD465  252, 267, 269
STAR*D  54, 111, 152, 161
statistical analysis
  bipolar disorder trials
    B-A-B-A (off-on-off-on)  160–1
    crossover  161–5
    inclusiveness-homogeneity balance  167
  N-of-1  159–60
  eating disorder trials  238–40
  methodological assumptions  385
STEP-BP 127, 152, 155, 161, 170

Stephenia sinica Diels 313

L-stepholidine 312–13, 320

stimulant therapy

ADHD 251–66

substance use disorders 210

Strattera (atomoxetine), ADHD 252, 259–61, 269

streamlining clinical trials 16

stroke

antipsychotic-related 367

emotional lability 184

substance use disorders (SUDs) 207–27

comorbidity 150, 151, 152, 220–1

definitions 208–9

pharmacotherapies 209–19

research issues 219–27

suicide and suicidal behavior

antidepressants 31–40, 114

mood disorders

bipolar disorder management 139–40

epidemiological data 106

neurobiological data 107

treatment selection factors 113–14

superiority trials, FDA reforms 23

susceptibility, gene-based patents 67–8, 69–83

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BP) 127, 152, 155, 161, 170

tailored drugs 54–5, 63

patents 68, 73–4

tamoxifen 52, 182

tardive dyskinesia (TD) 281, 318, 324, 341–2, 343

teratogen risk, clinical trials 87–98

testosterone therapy 113

tetabenazine 342

thalidomide 87–9, 91

thiamine 210

thioridazine 344, 349, 352, 367, 369

thromboembolism 367

thyroid function 137

thyroid hormones 113

tiagabine 134

topiramate

eating disorders 241

impulse control disorders 293, 300, 301, 303

post-traumatic stress disorder 201

substance use disorders 210, 213, 226

torsade de pointes (Tdp) 352–3

toxicity, herbal agents 323–4

tramadol 216

transcranial magnetic stimulation 113

transcription factors 47

trazodone 180, 181, 182

treatment drop-out see retention

trichotillomania (TTM) 289–90, 292, 296–9

tricyclic antidepressants

eating disorders 241

factors in choosing 111, 112, 114

panic disorder 197, 201

trichotillomania 296–9

utility of low-dose 180, 181–2, 184

urinary retention 365

US Congress 170–1

US FDA see Food and Drug Administration

vagus nerve stimulation 113

val/val genotype 51

val158met 51, 62–3, 65–6

valerian 323, 326

valproate

antipsychotic-related seizures 360

Asperger’s spectrum disorders 280

bipolar disorder

acute depression 130

acute mania 127–8, 129

combination therapies 153

cost-effectiveness 138, 139

Life Chart rating 156

maintenance 133, 153–4

prophylactic treatment 135

protective effect against mortality in 139

impulse control disorders 295, 301–4

PKC inhibition 52

substance use disorders 218

vasopressin (ADH) 357–9

venlafaxine

factors in choosing 112

generalized anxiety disorder 199, 201
venlafaxine (continued)
  social anxiety disorder 200, 201
  utility of low-dose 180, 182, 184
  viruses, gene therapy vectors 55
  vomiting 181
  Vyvanse (LDX) 252, 253–5, 269

weight gain 347–8, 350
withdrawal symptoms 210, 218, 369–70
women
  antipsychotic effects 355–6, 357
  childhood maltreatment 107, 116
  clinical trials 87–98
  low-dose antidepressants 182

mood disorder treatments 115, 116

Young Mania Rating Scale (YMRS) 154

ziprasidone
  adverse effects
    anticholinergic 365
    behavioral 340, 344, 345
    cardiovascular 351, 352, 353
    cataracts 369
    metabolic 347, 349
    neuroendocrine 355, 356, 358
    receptor binding affinity 339
    seizures 360
  bipolar disorder 128, 153, 340

Index compiled by Liz Granger